132. See WT/L/641 Amendment of the TRIPS Agreement (Decision of 6 December 2005), at (last visited May 1, 2006)
133. See Medecins Sans Frontieres, Chairman's Text Brings New Difficulties to WTO "Paragraph 6" (Aug. 27, 2003), at (Last visited Jan. 5, 2006).
134. Scott Miller, WTO Drug Pact Lifts Trade Talks, Wall St. J., Sept. 2, 2003, at A2.
135. 《执行决议》有三个段落与之相关，第2段、第4段、第5段。第4段内容为：“为了确保根据本《决议》中确立的制度进口的产品用于公共健康目的，“符合条件的进口成员方”应在力所能及的范围内采取所有合理措施防止实际已根据此制度进口其境内的产品再出口到它处。如果“符合条件的进口成员方”是难以执行本条款的发展中国家或最不发达国家成员方，发达国家成员方必须应请求或根据共同达成的条款和条件提供技术和金融协作，促进其执行本条款。”；第5段内容为：“各成员方应确保TRIPS协议所要求的有效法律手段的可获取性，以期防止在此制度下生产的产品进口并在其境内销售， 如有任何成员方认为，为此目的所采取的措施不够充分，可提出请求，TRIPS理事会将对此进行审议。”
136. 《执行决议》第11段为：“对所有成员方而言，本决议，包括其中授予的“放弃权”将于对TRIPS协议作出的修改替代现有的对该成员方生效的条款之日起终止。TRIPS理事会将于2003年底启动修改TRIPS协议的准备工作并希望在6个月内予以通过，该修改在适当之处将以本《决议》为基础，而且不作为《多哈部长宣言》（WT/MIN（01）/DEC/1）第45段中提到的谈判的一部分。”
137. Shapi Shacinda, WTO Rules Mean Life, Death to Africa, Houston Chron., Sept. 7, 2003, at 5, available at 2003 WL 57440840.
138. The General Council Chairperson’s Statement, available at (last visited Dec 10, 2005) 。
139. 参见前引132，Medecins Sans Frontieres文。
140. The General Council Chairperson's Statement, WTO 2003 News Items, Aug. 30, 2003, at (last visited Jan. 5, 2006); see also WTO NEWS 2003 Press Releases, Decision Removes Final Patent Obstacle to Cheap Drug Imports (Aug. 30, 2003), at (last visited Jan. 5, 2006). The Chairperson's Statement focused on the issue of diversion of drugs from their target market, a concern of pharmaceutical companies. See Chairperson's Statement.
141. See Star Ledger, Put Fighting Disease First, Sept. 10, 2003, at 14, available at 2003 WL 18727632.
142. Frederick M. Abbott, The WTO Medicines Decision: World Pharmaceutical Trade and the Protection of Public Health, 99 A.J.I.L. 317, 358 (2005).
143. Pavento et al., International Patent Protection for HIV-Related Therapies: Patent Attorneys' Perspective, 17 EMORY INT'L L. REV. 919, 923 (2003).
144. Divya Murthy, The Future of Compulsory Licensing: Deciphering the Doha Declaration on the TRIPS Agreement and Public Health, 17 Am. U. INT'L L. REV. 1299, 1324, 1329-32 (2002).
145. 印度利用了TRIPS协议第65条第4款的过渡期条款，该条款允许发展中国家将给与药品专利的时间推迟到2005年的1月1日。
146. See Carsten Fink, Patent Protection, Transnational Corporations, and Market Structure: A Simulation Study of the Indian Pharmaceutical Industry, 1 J. Industry, Competition & Trade 101, 106 (2001).
147. See D. G. Shah, The New Indian Patent Law and August 30 Decision: The Response of the Generic Industry, presentation to WHO-CIPIH Commission on Intellectual Property Rights, Innovation and Public Health, Geneva (Mar. 1, 2005).
148. 参见邓常春《近五年来印度〈专利法〉的修改对其制药业的影响》，载《南亚研究季刊》，2005年第2期，第32页以下。